Prophylactic Antibiotics After Cesarean

Surgical Site Infection Clinical Trial

— PACT  

Official title:

Prophylactic Antibiotics After Cesarean

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03187106
• Other study ID #: 17-0035
• Status: Completed
• Phase: Phase 1
• Start date: August 1, 2017
• Est. completion date: July 21, 2023

Study information

• Verified date: August 2023
• Source: The University of Texas Medical Branch, Galveston
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine if the addition of a 48-hour course of post-operative antibiotics to the recommended course of pre-operative antibiotics improves surgical site infection rate in patients who are obese and undergo Cesarean section after laboring.

Description:

The investigators propose the conduction of a prospective, randomized, double-blinded clinical trial to evaluate an alternative prophylactic regimen for the prevention of surgical site infection in women who are obese and have been laboring prior to their Cesarean section. This study is to be conducted by the Department of Obstetrics & Gynecology at John Sealy Hospital at the University of Texas Medical Branch in Galveston, Texas. The intervention being studied will be the administration of cephalexin and metronidazole post-operatively for 48 hours. The primary outcome measure will be surgical site infection (including superficial or deep incisional surgical site infection, endometritis, and other related infections, such as septic pelvic thrombophlebitis and abdominal or pelvic abscess) in the post-operative period. In order to most effectively and accurately analyze our primary and secondary research outcomes, the investigators will standardize our surgical operation techniques in all ways feasible. These recommendations will be in concordance with American College of Obstetrics and Gynecology recommendations, as those generally accepted in the medical literature. All patients will undergo surgery in the same small group of HEPA-filtered and positive air-pressure operating rooms. Appropriate limitations on number of surgeons and assistants scrubbed for surgery, as well as general OR traffic, will be enforced. Patients will undergo hair clipping of the incision site when appropriate. Chlorhexidine skin decontamination will be the standard surgical site preparation. An adhesive drape will be used. Prior to skin incision, cefazolin and azithromycin will be administered. All patients to be considered for recruitment to this study will be undergoing delivery at John Sealy Hospital at the University of Texas Medical Branch in Galveston, Texas. Patients with an elevated BMI >or =30 kg/m2 who undergo cesarean section after laboring will be considered for randomization either prior to delivery or in the first 7 hours after delivery, to accommodate the need for the first dose of study medication or placebo 8 hours after surgery. Only patients who agree to inclusion after informed consent will be randomized per protocol.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 321
• Est. completion date: July 21, 2023
• Est. primary completion date: July 21, 2023
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Women >18 and <50 years
• BMI >30kg/m2
• Decision by clinical team to perform Cesarean section
• Rupture of membranes (ROM) < 24 hours after onset of labor or during the course of labor (ROM defined by spontaneous or artificial rupture of the amniotic sac)

Exclusion Criteria:

• Subject unwilling or unable to provide consent
• No prenatal care or a non-UTMB subject who is unlikely to be followed up after delivery
• Fetal demise or major congenital anomaly
• Immunosuppressed subjects: i.e., taking systemic immunosuppressants or steroids (e.g. transplant subjects; not including steroids for lung maturity), HIV with CD4<200, or other
• Diagnosis or suspicion of chorioamnionitis prior to randomization
• Other planned post-operative antibiotic administration
• High likelihood of additional surgical procedure beyond cesarean (e.g. scheduled hysterectomy, bowel or adnexal surgery)
• Known allergy or contraindication to cephalosporins or metronidazole
• Incarcerated individuals

Related Conditions & MeSH terms

• Surgical Site Infection
• Surgical Wound Infection

Intervention

Drug:
• Cephalexin
Other name(s): Keflex (cephalexin) Cephalexin at 500 mg per oral every 8 hours for a total of 6 doses
• Placebo
Placebo representing standard of care
• Metronidazole
Other name(s): Flagyl (metronidazole) Metronidazole at 500 mg per oral every 8 hours for a total of 6 doses

Locations

Country	Name	City	State
United States	St. David's North Austin Medical Center	Austin	Texas
United States	University of Texas Medical Branch John Sealy Hospital	Galveston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
The University of Texas Medical Branch, Galveston

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Surgical site infection	Including superficial or deep incisional surgical site infection, endometritis, and other related infections, such as septic pelvic thrombophlebitis and abdominal or pelvic abscess	6 weeks postpartum
Secondary	Maternal mortality	Maternal death	6 weeks (42 days) postpartum
Secondary	Febrile morbidity	If the patient develops a measured temperate greater than or equal to 100.4 degrees Fahrenheit (or 38.0 degrees Celsius), she will have a postpartum fever.	6 weeks (42 days) postpartum
Secondary	Postpartum antibiotic use	We will assess via chart review and direct patient inquiry whether or not antibiotics were taken by the patient for any purpose during the six weeks (42 days) immediately following delivery.	6 weeks (42 days) postpartum
Secondary	Wound hematoma or seroma	Wound hematoma or seroma, as diagnosed by a medical provider, according to CDC guidelines for diagnosis of wound hematoma or seroma	6 weeks (42 days) postpartum
Secondary	Use of resources	We will note whether the patient required hospital re-admission, emergency department visits, or need for imaging or other invasive procedures	6 weeks (42 days) postpartum
Secondary	Other adverse events	Such as allergic reaction to study medications	6 weeks postpartum